Jiaoti Huang

List of Publications by Year
in descending order

183	10,550	34016	37111
papers	citations	52 h-index	96 g-index

189	189	189	14856
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Identification of a Cell of Origin for Human Prostate Cancer. Science, 2010, 329, 568-571.	6.0	500
2	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. Journal of Clinical Oncology, 2018, 36, 2492-2503.	0.8	477
3	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	13.5	459
4	Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth. Cancer Cell, 2011, 19, 792-804.	7.7	449
5	PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate, 2011, 71, 1668-1679.	1.2	365
6	Multifocality and Prostate Cancer Detection by Multiparametric Magnetic Resonance Imaging: Correlation with Whole-mount Histopathology. European Urology, 2015, 67, 569-576.	0.9	362
7	Prostate cancer detection with magnetic resonanceâ€ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer, 2016, 122, 884-892.	2.0	346
8	Value of Targeted Prostate Biopsy Using Magnetic Resonanceâ€“Ultrasound Fusion in Men with Prior Negative Biopsy and Elevated Prostate-specific Antigen. European Urology, 2014, 65, 809-815.	0.9	337
9	N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell, 2016, 29, 536-547.	7.7	278
10	Prostate cancerâ€“associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nature Medicine, 2017, 23, 1063-1071.	15.2	240
11	Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science, 2018, 362, 91-95.	6.0	217
12	Functional expression of sodium-glucose transporters in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4111-9.	3.3	209
13	Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. Cell, 2016, 166, 1041-1054.	13.5	206
14	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	9.4	198
15	Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology. Journal of Urology, 2017, 197, 320-326.	0.2	173
16	SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. Molecular Cell, 2015, 59, 917-930.	4.5	172
17	CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy. Cancer Research, 2015, 75, 950-962.	0.4	150
18	Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20111-20116.	3.3	144

#	Article	IF	Citations
19	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2021, 145, 461-493.	1.2	143
20	Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. European Urology, 2018, 73, 322-339.	0.9	130
21	Magnetic Resonance Imaging-Ultrasound Fusion Biopsy for Prediction of Final Prostate Pathology. Journal of Urology, 2014, 192, 1367-1373.	0.2	121
22	Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6810-6815.	3.3	120
23	Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies. Cancer Cell, 2019, 36, 17-34.e7.	7.7	119
24	The expanded role of fatty acid metabolism in cancer: new aspects and targets. Precision Clinical Medicine, 2019, 2, 183-191.	1.3	119
25	EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating miR-1 and Activating TWIST1. Cancer Research, 2015, 75, 3077-3086.	0.4	118
26	Neuroendocrine Differentiation in Prostate Cancer: A Mechanism of Radioresistance and Treatment Failure. Frontiers in Oncology, 2015, 5, 90.	1.3	116
27	Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer. Clinical Cancer Research, 2017, 23, 3428-3441.	3.2	109
28	Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate, 2006, 66, 1399-1406.	1.2	108
29	Characteristics of Detected and Missed Prostate Cancer Foci on 3-T Multiparametric MRI Using an Endorectal Coil Correlated With Whole-Mount Thin-Section Histopathology. American Journal of Roentgenology, 2015, 205, W87-W92.	1.0	98
30	Neuroendocrine differentiation in prostate cancer. American Journal of Translational Research (discontinued), 2009, 1, 148-62.	0.0	98
31	Differential Expression of Interleukin-8 and Its Receptors in the Neuroendocrine and Non-Neuroendocrine Compartments of Prostate Cancer. American Journal of Pathology, 2005, 166, 1807-1815.	1.9	96
32	Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value. Journal of Urology, 2016, 195, 1421-1427.	0.2	96
33	Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4473-E4482.	3.3	96
34	Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nature Communications, 2018, 9, 3600.	5.8	96
35	Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. Cell Reports, 2016, 17, 2596-2606.	2.9	94
36	Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4482-4487.	3.3	92

#	Article	IF	Citations
37	Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. Cancer, 2015, 121, 3240-3251.	2.0	89
38	Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial. Journal of Urology, 2016, 196, 68-75.	0.2	88
39	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12315-12323.	3.3	87
40	Purification and direct transformation of epithelial progenitor cells from primary human prostate. Nature Protocols, 2011, 6, 656-667.	5.5	86
41	A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers. Cell Reports, 2018, 24, 3353-3366.e5.	2.9	80
42	Agonist and antagonist switch <scp>DNA</scp> motifs recognized by human androgen receptor in prostate cancer. EMBO Journal, 2015, 34, 502-516.	3.5	74
43	Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer. Nature Communications, 2015, 6, 8323.	5.8	74
44	N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway. Molecular Cancer, 2019, 18, 11.	7.9	70
45	Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer. Journal of Urology, 2017, 197, 632-639.	0.2	69
46	FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. Modern Pathology, 2017, 30, 1262-1272.	2.9	67
47	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 531-538.	2.0	66
48	Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells. Oncotarget, 2015, 6, 23959-23986.	0.8	65
49	Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. Science Translational Medicine, 2019, 11, .	5.8	63
50	Cav1.3 channel Î±1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers11This work was partially supported by grants from DoD PCRP program (W81XWH-09-1-0455) and KUMC Valk Foundation to Dr Benyi Li, and grants from China Natural Science Foundation to Dr Benyi Li (NSFC #81172427) and Dr Jun Yang (NSFC #81101927). This project was also supported by the â€œChutian Scholarâ€•program funded by Hubei Province of China dedicated to China Three Gorges University.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 524-536.	0.8	61
51	p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma. Molecular Cancer Research, 2015, 13, 584-591.	1.5	61
52	The Role of Magnetic Resonance Imaging in Delineating Clinically Significant Prostate Cancer. Urology, 2014, 83, 369-375.	0.5	60
53	LIN28B promotes the development of neuroendocrine prostate cancer. Journal of Clinical Investigation, 2020, 130, 5338-5348.	3.9	60
54	SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. Developmental Cell, 2019, 48, 329-344.e5.	3.1	53

#	Article	IF	Citations
55	Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer. Science Signaling, 2017, 10, .	1.6	52
56	Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Molecular Cancer Research, 2019, 17, 1235-1240.	1.5	51
57	Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation. Asian Journal of Andrology, 2014, 16, 541.	0.8	51
58	All-trans retinoic acids induce differentiation and sensitize a radioresistant breast cancer cells to chemotherapy. BMC Complementary and Alternative Medicine, 2016, 16, 113.	3.7	49
59	Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?. American Journal of Roentgenology, 2017, 209, 1272-1277.	1.0	49
60	Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy. Journal of Urology, 2018, 199, 453-458.	0.2	47
61	Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6457-E6466.	3.3	44
62	Long-chain fatty acyl-CoA synthetase 1 promotes prostate cancer progression by elevation of lipogenesis and fatty acid beta-oxidation. Oncogene, 2021, 40, 1806-1820.	2.6	43
63	Pre-existing Castration-resistant Prostate Cancerâ€“like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy. European Urology, 2022, 81, 446-455.	0.9	41
64	Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E172-81.	3.3	40
65	Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).. Journal of Clinical Oncology, 2015, 33, 5003-5003.	0.8	40
66	In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer. Abdominal Radiology, 2016, 41, 954-962.	1.0	38
67	The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma. Molecular Cancer Research, 2016, 14, 344-353.	1.5	37
68	Targeting therapy-resistant prostate cancer via a direct inhibitor of the human heat shock transcription factor 1. Science Translational Medicine, 2020, 12, .	5.8	36
69	Redefining the Autonomic Nerve Distribution of the Bladder Using 3-Dimensional Image Reconstruction. Journal of Urology, 2015, 194, 1661-1667.	0.2	34
70	A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	34
71	Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 952-957.	0.8	33
72	Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46. Clinical Cancer Research, 2019, 25, 4128-4140.	3.2	31

#	Article	IF	Citations
73	PRMT5 Cooperates with pICln to Function as a Master Epigenetic Activator of DNA Double-Strand Break Repair Genes. IScience, 2020, 23, 100750.	1.9	31
74	CTâ€“Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. Journal of Vascular and Interventional Radiology, 2017, 28, 1073-1081.e1.	0.2	30
75	Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2Î±. European Journal of Cancer, 2014, 50, 1531-1540.	1.3	29
76	Multiregional Radiogenomic Assessment of Prostate Microenvironments with Multiparametric MR Imaging and DNA Whole-Exome Sequencing of Prostate Glands with Adenocarcinoma. Radiology, 2017, 284, 109-119.	3.6	29
77	Evaluation and Comparison of Contemporary Energy-Based Surgical Vessel Sealing Devices. Journal of Endourology, 2018, 32, 329-337.	1.1	29
78	Clonality of Combined Tumors. Archives of Pathology and Laboratory Medicine, 2002, 126, 437-441.	1.2	29
79	Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma. Molecular Carcinogenesis, 2015, 54, 900-907.	1.3	28
80	A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Nonâ€“Small Cell Lung Cancer. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 263-269.	0.6	28
81	Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Molecular Cancer Research, 2017, 15, 1221-1229.	1.5	27
82	Molecular determinants for enzalutamide-induced transcription in prostate cancer. Nucleic Acids Research, 2019, 47, 10104-10114.	6.5	27
83	Adrenal Teratoma: a Case Series and Review of the Literature. Endocrine Pathology, 2017, 28, 152-158.	5.2	26
84	Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6. Cancer Letters, 2017, 384, 1-8.	3.2	26
85	Plectin is a regulator of prostate cancer growth and metastasis. Oncogene, 2021, 40, 663-676.	2.6	26
86	Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer. Practical Radiation Oncology, 2015, 5, 411-416.	1.1	25
87	SRRM4 gene expression correlates with neuroendocrine prostate cancer. Prostate, 2019, 79, 96-104.	1.2	25
88	Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance. Communications Biology, 2021, 4, 22.	2.0	25
89	Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer. Clinical Cancer Research, 2017, 23, 985-991.	3.2	24
90	The size of cell-free mitochondrial DNA in blood is inversely correlated with tumor burden in cancer patients. Precision Clinical Medicine, 2019, 2, 131-139.	1.3	24

#	Article	IF	Citations
91	Morphologic Spectrum of Neuroendocrine Tumors of the Prostate: An Updated Review. Archives of Pathology and Laboratory Medicine, 2020, 144, 320-325.	1.2	24
92	EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer. Oncogene, 2020, 39, 6757-6775.	2.6	23
93	Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer. Cancer Letters, 2019, 440-441, 35-46.	3.2	22
94	Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer. Nucleic Acids Research, 2021, 49, 4971-4988.	6.5	22
95	Biased Expression of the FOXP3Î”3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance. Clinical Cancer Research, 2016, 22, 5349-5361.	3.2	21
96	Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk. Clinical Cancer Research, 2017, 23, 6-8.	3.2	21
97	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. JAMA Oncology, 2021, 7, 1644.	3.4	21
98	Neuroendocrine cells of the prostate: Histology, biological functions, and molecular mechanisms. Precision Clinical Medicine, 2021, 4, 25-34.	1.3	21
99	Roles of Alternative RNA Splicing of the Bif-1 Gene by SRRM4 During the Development of Treatment-induced Neuroendocrine Prostate Cancer. EBioMedicine, 2018, 31, 267-275.	2.7	20
100	A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 563-572.	3.3	20
101	RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression. European Urology, 2019, 76, 157-166.	0.9	19
102	ATM deficiency promotes progression of CRPC by enhancing Warburg effect. Endocrine-Related Cancer, 2019, 26, 59-71.	1.6	19
103	Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells. Archives of Medical Research, 2015, 46, 642-650.	1.5	18
104	Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer. Cancer Research, 2020, 80, 4904-4917.	0.4	18
105	Glycosylation Changes in Prostate Cancer Progression. Frontiers in Oncology, 2021, 11, 809170.	1.3	18
106	Gli Transcription Factors Mediate the Oncogenic Transformation of Prostate Basal Cells Induced by a Kras-Androgen Receptor Axis. Journal of Biological Chemistry, 2016, 291, 25749-25760.	1.6	17
107	Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer. Journal of Urology, 2018, 199, 98-105.	0.2	17
108	Function and molecular mechanisms of neuroendocrine cells in prostate cancer. , 2007, 29, 128-38.		17

#	Article	IF	Citations
109	Urinary Pubic Symphysis Fistula Leads to Histopathologic Osteomyelitis in Prostate Cancer Survivors. Urology, 2021, 148, 297-301.	0.5	16
110	Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT).. Journal of Clinical Oncology, 2016, 34, 5019-5019.	0.8	16
111	Intrarenal and Extrarenal Autonomic Nervous System Redefined. Journal of Urology, 2014, 191, 1060-1065.	0.2	15
112	New prostate cancer prognostic grade group (PGG): Can multiparametric MRI (mpMRI) accurately separate patients with low-, intermediate-, and high-grade cancer?. Abdominal Radiology, 2018, 43, 702-712.	1.0	15
113	UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression. BMC Cancer, 2017, 17, 463.	1.1	13
114	Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making. Radiologic Clinics of North America, 2018, 56, 239-250.	0.9	13
115	Making a Tissue Microarray. Methods in Molecular Biology, 2019, 1897, 313-323.	0.4	13
116	Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation. Molecular Cancer Therapeutics, 2022, 21, 448-459.	1.9	13
117	A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 762-769.	2.0	13
118	Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer. Oncogene, 2022, 41, 1140-1154.	2.6	12
119	PIP5K1Î± inhibition as a therapeutic strategy for prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12578-12579.	3.3	11
120	Multiparametric Ultrasound for Targeting Prostate Cancer: Combining ARFI, SWEI, QUS and B-Mode. Ultrasound in Medicine and Biology, 2020, 46, 3426-3439.	0.7	11
121	Overexpression of Human Carcinomaâ€“Associated Antigen in Esophageal Adenocarcinoma and Its Precursor Lesions. American Journal of Clinical Pathology, 2004, 122, 747-751.	0.4	10
122	DHX15 is upâ€regulated in castrationâ€resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations. Prostate, 2019, 79, 657-666.	1.2	10
123	Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2020, 26, 4616-4624.	3.2	10
124	Carbohydrate Microarrays Identify Blood Group Precursor Cryptic Epitopes as Potential Immunological Targets of Breast Cancer. Journal of Immunology Research, 2015, 2015, 1-9.	0.9	9
125	Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making. Urologic Clinics of North America, 2018, 45, 455-466.	0.8	9
126	Molecular pathology of prostate cancer revealed by next-generation sequencing. Current Opinion in Urology, 2013, 23, 189-193.	0.9	8

#	Article	IF	Citations
127	Predicting clinical outcome of therapy-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11090-11092.	3.3	8
128	Detection and Localization of Prostate Cancer at 3-T Multiparametric MRI Using PI-RADS Segmentation. American Journal of Roentgenology, 2019, 212, W122-W131.	1.0	8
129	Prostate Cancer Cell Phenotypes Remain Stable Following PDE5 Inhibition in the Clinically Relevant Range. Translational Oncology, 2020, 13, 100797.	1.7	8
130	Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.. Journal of Clinical Oncology, 2021, 39, 89-89.	0.8	8
131	Frequent Expression of Human Carcinoma-Associated Antigen, a Mucin-Type Glycoprotein, in Cells of Prostatic Carcinoma. Archives of Pathology and Laboratory Medicine, 2004, 128, 1412-1417.	1.2	8
132	Overexpression of Human Carcinomaâ€“Associated Antigen in Urothelial Carcinoma of the Bladder. Archives of Pathology and Laboratory Medicine, 2004, 128, 785-787.	1.2	8
133	Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer. Asian Journal of Urology, 2019, 6, 91-98.	0.5	6
134	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 295.e1-295.e8.	0.8	6
135	Overexpression of human carcinoma-associated antigen in esophageal adenocarcinoma and its precursor lesions. American Journal of Clinical Pathology, 2004, 122, 747-51.	0.4	6
136	TCF7L1 regulates cytokine response and neuroendocrine differentiation of prostate cancer. Oncogenesis, 2021, 10, 81.	2.1	6
137	Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 3001-3001.	0.8	6
138	Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells. Scientific Reports, 2018, 8, 12507.	1.6	5
139	PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer. British Journal of Cancer, 2022, 126, 778-790.	2.9	5
140	Pyruvate kinase L/R links metabolism dysfunction to neuroendocrine differentiation of prostate cancer by ZBTB10 deficiency. Cell Death and Disease, 2022, 13, 252.	2.7	5
141	Three-dimensional localization and targeting of prostate cancer foci with imaging and histopathologic correlation. Current Opinion in Urology, 2018, 28, 506-511.	0.9	4
142	The promise of immunotherapy in genitourinary malignancies. Precision Clinical Medicine, 2018, 1, 97-101.	1.3	4
143	Initial Evaluation of a Novel Modulated Radiofrequency-based Bladder Denervation Device. Urology, 2019, 134, 237-242.	0.5	4
144	Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 931.e9-931.e16.	0.8	4

#	Article	IF	Citations
145	A Hybrid Humanâ€“Machine Learning Approach for Screening Prostate Biopsies Can Improve Clinical Efficiency Without Compromising Diagnostic Accuracy. Archives of Pathology and Laboratory Medicine, 2022, 146, 727-734.	1.2	4
146	Serum lipid profiles and aggressive prostate cancer. Asian Journal of Andrology, 2015, 17, 336.	0.8	4
147	Transcription recycling assays identify PAF1 as a driver for RNA Pol II recycling. Nature Communications, 2021, 12, 6318.	5.8	4
148	Metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas (NECs) as novel indications for rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC).. Journal of Clinical Oncology, 2016, 34, 11611-11611.	0.8	3
149	Luminal and basal subtyping of metastatic castration-resistant prostate cancer (mCRPC) and its clinical implications.. Journal of Clinical Oncology, 2018, 36, 197-197.	0.8	3
150	Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell/neuroendocrine prostate cancer (t-SCNC) may evolve from mCRPC adenocarcinoma (adeno)â€”Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).. Journal of Clinical Oncology, 2020, 38, 158-158.	0.8	3
151	Alternative Splicing Provides a Novel Molecular Mechanism for Prostatic Small-cell Neuroendocrine Carcinoma. European Urology, 2017, 71, 79-80.	0.9	2
152	Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. Abdominal Radiology, 2018, 43, 2487-2496.	1.0	2
153	Progression of low- to high-grade prostate cancer: Molecular profiling of tissue obtained by serial targeted biopsy.. Journal of Clinical Oncology, 2015, 33, 5017-5017.	0.8	2
154	Persistence of AR signaling in small cell neuroendocrine prostate cancer (SCNC) and intermediate atypical carcinoma (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).. Journal of Clinical Oncology, 2016, 34, 5045-5045.	0.8	2
155	Persistence of androgen receptor (AR) expression in patients (pts) with small cell prostate cancer (SCPC): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).. Journal of Clinical Oncology, 2016, 34, 288-288.	0.8	2
156	Prostate cancer: molecular and cellular mechanisms and their implications in therapy resistance and disease progression. Asian Journal of Andrology, 2019, 21, 213.	0.8	2
157	HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study. Molecular Cancer Therapeutics, 2022, 21, 217-226.	1.9	2
158	Prostate Cancer Detection Rate of Freehand versus 3-Dimensional Template Mapping Biopsy Using a Magnetic Resonance Imaging-Ultrasound Fusion Device in Biopsy NaÃ¯ve Men. Journal of Urology, 2020, 203, 699-705.	0.2	2
159	Dysplastic ("in-situ") Lesions in multofocal renal oncocytomas (oncocytosis). International Journal of Clinical and Experimental Pathology, 2009, 2, 583-7.	0.5	2
160	Phosphorylated MED1 links transcription recycling and cancer growth. Nucleic Acids Research, 2022, 50, 4450-4463.	6.5	2
161	Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry. Prostate Cancer and Prostatic Diseases, 2022, 25, 513-523.	2.0	2
162	Multiparametric Ultrasound for the Targeting of Prostate Cancer using ARFI, SWEI, B-mode, and QUS. , 2019, , .		1

#	Article	IF	Citations
163	PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 509-513.	0.9	1
164	Tissue clearing techniques for threeâ€dimensional optical imaging of intact human prostate and correlations with multiâ€parametric MRI. Prostate, 2021, 81, 521-529.	1.2	1
165	Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2019, 37, 577-577.	0.8	1
166	A pleiotropic ATM variant (rs1800057 C>G) is associated with risk of multiple cancers. Carcinogenesis, 2021, , .	1.3	1
167	Fasting times in serum PSA assay. Asian Journal of Andrology, 2014, 16, 786.	0.8	1
168	Cover Picture: Highly Efficient Capture of Circulating Tumor Cells by Using Nanostructured Silicon Substrates with Integrated Chaotic Micromixers (Angew. Chem. Int. Ed. 13/2011). Angewandte Chemie - International Edition, 2011, 50, 2857-2857.	7.2	0
169	Reply to A. Dalla Volta et al. Journal of Clinical Oncology, 2019, 37, 351-352.	0.8	0
170	Quantifying the ki-67 heterogeneity profile in prostate cancer.. Journal of Clinical Oncology, 2013, 31, 73-73.	0.8	0
171	Investigating the association of cytoplasmic and nuclear HIF-2 expression with cancer specific survival (CSS) in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 387-387.	0.8	0
172	Molecular profiling of metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).. Journal of Clinical Oncology, 2014, 32, 5088-5088.	0.8	0
173	Morphological Subsets of Circulating Tumor Cells in Advanced Prostate Cancers: A Potential Biomarker for Patients with Visceral Metastases. FASEB Journal, 2015, 29, 417.2.	0.2	0
174	Serum neuroendocrine (NE) markers and clinical characteristics of treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) in men with metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team.. Journal of Clinical Oncology, 2018, 36, 278-278.	0.8	0
175	DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team.. Journal of Clinical Oncology, 2018, 36, 5039-5039.	0.8	0
176	Clinical and genomic hallmarks of low PSA secretors in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 5051-5051.	0.8	0
177	Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2019, 37, e14259-e14259.	0.8	0
178	Copy number analysis to identify tumor suppressor genes associated with enzalutamide (Enza) resistance and poor prognosis in metastatic castration-resistant prostate cancer (mCRPC) patients.. Journal of Clinical Oncology, 2019, 37, 5011-5011.	0.8	0
179	ADRB2 expression in progressive metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2020, 38, 145-145.	0.8	0
180	Circulating tumor cells with small nuclear size: A novel biomarker for survival and clinical outcomes in advanced prostate cancer.. Journal of Clinical Oncology, 2020, 38, e17512-e17512.	0.8	0

#	Article	IF	Citations
181	Association of very small nuclear circulating tumor cell (vsnCTC) with clinical outcomes in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2020, 38, 168-168.	0.8	0
182	Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 167-167.	0.8	0
183	Transcriptional profiling of matched biopsies reveals molecular determinants of enzalutamide resistance.. Journal of Clinical Oncology, 2022, 40, 5058-5058.	0.8	0